Millennium Management’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Millennium Management’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-589,987	Closed	-$13.6M	–	6865
2020 Q4	$13.6M	Buy	589,987 +523,965	+794%	+$6.64M	0.01%	1398
2020 Q3	$672	Sell	66,022 -61,789	-48%	-$829K	﹤0.01%	3412
2020 Q2	$1.9M	Buy	127,811 +31,124	+32%	+$479K	﹤0.01%	2573
2020 Q1	$1.18M	Buy	+96,687	New	+$1.54M	﹤0.01%	2363
2019 Q4	–	Sell	-50,338	Closed	-$618K	–	4820
2019 Q3	$618K	Sell	50,338 -129,915	-72%	-$1.47M	﹤0.01%	3117
2019 Q2	$2.38M	Buy	+180,253	New	+$2.63M	﹤0.01%	2295

Millennium Management's PRVL Position: Q1 2021 in Review

Millennium Management sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 589,987 shares — an estimated $13.6M sold.

Millennium Management first reported a position in PRVL in Q2 2019 and held it in 6 quarters. The position peaked at $13.6M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Millennium Management reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Millennium Management sold 589,987 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $13.6M.
Millennium Management first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 6 quarters.
Millennium Management's Prevail Therapeutics Inc. Common Stock position peaked at $13.6M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Millennium Management's 13F filing for Q1 2021, filed 17 May 2021.